Adverse effects may indicate drug efficacy. Therefore, discontinuation should be discussed carefully. As has reinstitution of treatment. For review of pulmonary and nonpulmonary AEs, see under PMID�26371282,�27532025. Guidelines are available at manufacturers' websites

Last update : 04/11/2017